Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

636 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Maron MS, Mahmod M, Abd Samat AH, Choudhury L, Massera D, Phelan DMJ, Cresci S, Martinez MW, Masri A, Abraham TP, Adler E, Wever-Pinzon O, Nagueh SF, Lewis GD, Chamberlin P, Patel J, Yavari A, Dehbi HM, Sarwar R, Raman B, Valkovič L, Neubauer S, Udelson JE, Watkins H. Maron MS, et al. Among authors: watkins h. J Am Coll Cardiol. 2024 May 28;83(21):2037-2048. doi: 10.1016/j.jacc.2024.03.387. Epub 2024 Apr 8. J Am Coll Cardiol. 2024. PMID: 38599256 Free article. Clinical Trial.
Metabolic profiling of aortic stenosis and hypertrophic cardiomyopathy identifies mechanistic contrasts in substrate utilization.
Pal N, Acharjee A, Ament Z, Dent T, Yavari A, Mahmod M, Ariga R, West J, Steeples V, Cassar M, Howell NJ, Lockstone H, Elliott K, Yavari P, Briggs W, Frenneaux M, Prendergast B, Dwight JS, Kharbanda R, Watkins H, Ashrafian H, Griffin JL. Pal N, et al. Among authors: watkins h. FASEB J. 2024 Mar 31;38(6):e23505. doi: 10.1096/fj.202301710RR. FASEB J. 2024. PMID: 38507255
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP; SEQUOIA-HCM Investigators. Maron MS, et al. Among authors: watkins h. N Engl J Med. 2024 May 30;390(20):1849-1861. doi: 10.1056/NEJMoa2401424. Epub 2024 May 13. N Engl J Med. 2024. PMID: 38739079 Clinical Trial.
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
Coats CJ, Masri A, Barriales-Villa R, Abraham TP, Brinkley DM, Claggett BL, Hagege A, Hegde SM, Ho CY, Kulac IJ, Lee MMY, Maron MS, Olivotto I, Owens AT, Solomon SD, Tfelt-Hansen J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Januzzi JL. Coats CJ, et al. Among authors: watkins h. Eur Heart J. 2024 Nov 8;45(42):4464-4478. doi: 10.1093/eurheartj/ehae590. Eur Heart J. 2024. PMID: 39217447 Free PMC article. Clinical Trial.
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Kulac I, Lee MMY, Lewis GD, Ma CS, Michels M, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins HC, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Olivotto I; SEQUOIA-HCM Investigators. Maron MS, et al. Among authors: watkins hc. J Am Coll Cardiol. 2024 Nov 5;84(19):1821-1831. doi: 10.1016/j.jacc.2024.09.003. Epub 2024 Sep 30. J Am Coll Cardiol. 2024. PMID: 39352339 Free article. Clinical Trial.
Myocardial Disarray and Fibrosis across Hypertrophic Cardiomyopathy Stages Associate with ECG Markers of Arrhythmic Risk.
Ashkir Z, Samat AHA, Ariga R, Finnigan L, Jermy S, Akhtar MA, Sarto G, Murthy P, Wong B, Cassar MB, Beyhoff N, Wicks EW, Thomson K, Mahmod M, Tunnicliffe L, Neubauer S, Watkins H, Raman B. Ashkir Z, et al. Among authors: watkins h. Eur Heart J Cardiovasc Imaging. 2024 Oct 17:jeae260. doi: 10.1093/ehjci/jeae260. Online ahead of print. Eur Heart J Cardiovasc Imaging. 2024. PMID: 39417278
Comparing the effects of chemical Ca2+ dyes and R-GECO on contractility and Ca2+ transients in adult and human iPSC cardiomyocytes.
Robinson P, Sparrow AJ, Psaras Y, Steeples V, Simon JN, Broyles CN, Chang YF, Brook FA, Wang YJ, Blease A, Zhang X, Abassi YA, Geeves MA, Toepfer CN, Watkins H, Redwood C, Daniels MJ. Robinson P, et al. Among authors: watkins h. J Mol Cell Cardiol. 2023 Jul;180:44-57. doi: 10.1016/j.yjmcc.2023.04.008. Epub 2023 Apr 29. J Mol Cell Cardiol. 2023. PMID: 37127261 Free PMC article.
Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy.
Tahir UA, Kolm P, Kwong RY, Desai MY, Dolman SF, Deng S, Appelbaum E, Desvigne-Nickens P, DiMarco JP, Tiwari G, Friedrich MG, Zelaya-Portillo JH, Jerosch-Herold M, Kim DY, Maron MS, Piechnik SK, Schulz-Menger J, Watkins H, Weintraub WS, Neubauer S, Kramer CM, Jarolim P, Gerszten RE, Ho CY; HCMR Investigators. Tahir UA, et al. Among authors: watkins h. Circ Heart Fail. 2024 Dec;17(12):e011707. doi: 10.1161/CIRCHEARTFAILURE.124.011707. Epub 2024 Nov 5. Circ Heart Fail. 2024. PMID: 39498543
Considerations for drug trials in hypertrophic cardiomyopathy.
Farrant JP, Schmitt M, Reid AB, Garratt CJ, Newman WG, Malhotra A, Beynon R, Mahmod M, Raman B, Cooper RM, Dawson D, Green T, Prasad SK, Singh A, Dodd S, Watkins H, Neubauer S, Miller CA. Farrant JP, et al. Among authors: watkins h. ESC Heart Fail. 2024 Oct 27. doi: 10.1002/ehf2.15138. Online ahead of print. ESC Heart Fail. 2024. PMID: 39462184 Free article. Review.
636 results